{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:07:48Z","timestamp":1784837268378,"version":"3.55.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cisplatin-based neoadjuvant chemotherapy (NAC) improves survival in muscle-invasive urothelial cancer (MIUC), yet pathological complete response (pCR) is achieved in a minority of patients. Relative dose intensity (RDI) is a potentially modifiable determinant of chemotherapy efficacy, but its impact during NAC in MIUC remains unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective study included patients with MIUC treated with cisplatin\u2013gemcitabine NAC followed by radical cystectomy. Relative dose intensity was calculated from original administration records and categorized as \u226585% vs &amp;lt;85%. The primary endpoint was pCR (ypT0N0M0). Secondary endpoints included overall survival (OS) and event-free survival (EFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 330 patients were included; 66% maintained RDI\u2009\u2265\u200985%. Overall pCR rate was 25.2%. Patients with RDI\u2009\u2265\u200985% achieved higher pCR rates compared with those with RDI\u2009&amp;lt;\u200985% (29.7% vs 16.2%; P\u2009=\u2009.008). Relative dose intensity \u2009\u2265\u200985% remained independently associated with pCR in multivariable analysis (odds ratio\u2009=\u20092.10; P\u2009=\u2009.032). Preserved RDI was also associated with improved EFS (hazard ratio [HR]\u2009=\u20090.65; P\u2009=\u2009.039) and OS (HR\u2009=\u20090.53; P\u2009=\u2009.026) at univariate analysis. Achievement of pCR was strongly associated with superior EFS (HR\u2009=\u20090.23; P\u2009&amp;lt;\u2009.001) and OS (HR\u2009=\u20090.35; P\u2009=\u2009.009).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Preservation of cisplatin RDI\u2009\u2265\u200985% during NAC is independently correlated with higher pCR rates and associated to a better survival trend in MIUC. Optimization of chemotherapy delivery represents a clinically actionable strategy to enhance neoadjuvant efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag256","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:07:54Z","timestamp":1782922074000},"source":"Crossref","is-referenced-by-count":0,"title":["The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2412-1310","authenticated-orcid":false,"given":"Giuseppe","family":"Neola","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, Via Sergio Pansini, 5, Naples, 80131,","place":["Italy"]},{"name":"Portsmouth Hospitals University NHS Trust , Portsmouth, PO63LY,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5699-4958","authenticated-orcid":false,"given":"Fabiano","family":"Flauto","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, Via Sergio Pansini, 5, Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Caso","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, Via Sergio Pansini, 5, Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Montuori","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, Via Sergio Pansini, 5, Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[{"name":"Oncology Unit 3, Istituto Oncologico Veneto - IOV IRCCS , Padova, 35128,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Lai","sequence":"additional","affiliation":[{"name":"Oncology Unit 3, Istituto Oncologico Veneto - IOV IRCCS , Padova, 35128,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0764-3650","authenticated-orcid":false,"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[{"name":"Portsmouth Hospitals University NHS Trust , Portsmouth, PO63LY,","place":["UK"]},{"name":"Faculty of Science & Health, School of Pharmacy & Biomedical Sciences, University of Portsmouth , Portsmouth, PO63LY,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7877-8988","authenticated-orcid":false,"given":"Michele","family":"Maffezzoli","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University Hospital of Parma\u2014Medical Oncology Unit, University of Parma , Parma, 43126,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimma","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari , Bari, 70124,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[{"name":"Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna, 40138,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mollica","sequence":"additional","affiliation":[{"name":"Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna, 40138,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Scagliarini","sequence":"additional","affiliation":[{"name":"UOC di Oncologia, Azienda Ospedaliera di Rilievo Nazionale Cardarelli di Napoli , Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-714X","authenticated-orcid":false,"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, 71122,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology\u2014Fondazione IRCCS Istituto Nazionale dei Tumori di Milano , Milan, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rametta","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology\u2014Fondazione IRCCS Istituto Nazionale dei Tumori di Milano , Milan, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital , Milan, 20132,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Facchini","sequence":"additional","affiliation":[{"name":"Oncology Unit, S. Maria Delle Grazie Hospital , Pozzuoli, Naples, 80078,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Lenci","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Azienda Ospedaliera Ospedali Riuniti Marche Nord , Pesaro, 61121,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Tambaro","sequence":"additional","affiliation":[{"name":"Uro-Gynecological Oncology, Istituto Nazionale Tumori\u2014IRCCS\u2014Fondazione G. Pascale , Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Grillone","sequence":"additional","affiliation":[{"name":"SOC Oncologia, PO Pugliese-Ciaccio, Azienda Ospedaliera Universitaria Renato Dulbecco , Catanzaro, 88100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8045-3460","authenticated-orcid":false,"given":"Davide","family":"Bosso","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Ospedale del Mare , Naples, 80147,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Crocetto","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II , Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Imbimbo","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II , Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3624-224X","authenticated-orcid":false,"given":"Alberto","family":"Servetto","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, Via Sergio Pansini, 5, Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-260X","authenticated-orcid":false,"given":"Roberto","family":"Bianco","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, Via Sergio Pansini, 5, Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7205-5105","authenticated-orcid":false,"given":"Luigi","family":"Formisano","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, Via Sergio Pansini, 5, Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"2026072315263731600_oyag256-B1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"2026072315263731600_oyag256-B2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"2026072315263731600_oyag256-B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"2026072315263731600_oyag256-B4","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.2217\/fon-2021-0273","article-title":"Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: phase III KEYNOTE-866 and KEYNOTE-905\/EV-303","volume":"17","author":"Galsky","year":"2021","journal-title":"Future Oncol"},{"key":"2026072315263731600_oyag256-B5","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2026072315263731600_oyag256-B6","doi-asserted-by":"publisher","first-page":"116102","DOI":"10.1016\/j.ejca.2025.116102","article-title":"Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer","volume":"232","author":"Buonaiuto","year":"2025","journal-title":"Eur J Cancer (1965)"},{"key":"2026072315263731600_oyag256-B7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.clbc.2018.02.003","article-title":"Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer","volume":"18","author":"Denduluri","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"2026072315263731600_oyag256-B8","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00520-019-04875-1","article-title":"Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer","volume":"28","author":"Crawford","year":"2020","journal-title":"Support Care Cancer"},{"key":"2026072315263731600_oyag256-B9","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","article-title":"Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The cancer and leukemia group B","volume":"90","author":"Budman","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2026072315263731600_oyag256-B10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.21873\/anticanres.14863","article-title":"Impact of the relative dose intensity of neoadjuvant chemotherapy with anthracycline followed by taxane on the survival of patients with human epidermal growth factor receptor 2-negative breast cancer: the JONIE1 study","volume":"41","author":"Yamada","year":"2021","journal-title":"Anticancer Res"},{"key":"2026072315263731600_oyag256-B11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000528937","article-title":"Impact of relative dose intensity of docetaxel, cisplatin, and 5-fluorouracil neoadjuvant chemotherapy on survival of esophageal squamous cell cancer patients","volume":"101","author":"Shiraishi","year":"2023","journal-title":"Oncology"},{"key":"2026072315263731600_oyag256-B12","doi-asserted-by":"publisher","first-page":"e1609","DOI":"10.1002\/onco.13822","article-title":"Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis","volume":"26","author":"Nielson","year":"2021","journal-title":"Oncologist"},{"key":"2026072315263731600_oyag256-B13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1200\/JCO.1993.11.3.400","article-title":"Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC","volume":"11","author":"Scher","year":"1993","journal-title":"J Clin Oncol"},{"key":"2026072315263731600_oyag256-B14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2026072315263731600_oyag256-B15","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1177\/10781552231214467","article-title":"Relative dose intensity of taxane-based chemotherapy in breast cancer patients in a tertiary hospital","volume":"30","author":"Helwani","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"2026072315263731600_oyag256-B16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00280-024-04665-5","article-title":"Postoperative chemotherapy relative dose intensity and overall survival in patients with colon cancer","volume":"94","author":"Brown","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026072315263731600_oyag256-B17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1177\/10781552231212206","article-title":"Impact of relative dose intensity on pathologic complete response in human epidermal growth factor receptor 2 positive breast cancer patients receiving neoadjuvant TCHP","volume":"30","author":"Collette","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"2026072315263731600_oyag256-B18","author":"The Jamovi Project","year":"2022"},{"key":"2026072315263731600_oyag256-B19","author":"R Core Team","year":"2021"},{"key":"2026072315263731600_oyag256-B20","author":"Harrison","year":"2019"},{"key":"2026072315263731600_oyag256-B21","author":"Therneau","year":"2019"},{"key":"2026072315263731600_oyag256-B22","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1200\/JCO.23.00307","article-title":"Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the society for immunotherapy of cancer and the international bladder cancer group","volume":"41","author":"Kamat","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026072315263731600_oyag256-B23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41585-021-00505-w","article-title":"Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US food and drug administration and bladder cancer advocacy network workshop","volume":"19","author":"Chang","year":"2022","journal-title":"Nat Rev Urol"},{"key":"2026072315263731600_oyag256-B24","first-page":"64","article-title":"Platinum dose-intensity","volume":"6","author":"Los","year":"1996","journal-title":"J Infus Chemother"},{"key":"2026072315263731600_oyag256-B25","doi-asserted-by":"publisher","first-page":"E459","DOI":"10.1188\/12.ONF.E459-E467","article-title":"Relative dose intensity\u2014improving treatment and outcomes in early-stage breast cancer: a retrospective study","volume":"39","author":"Griffin","year":"2012","journal-title":"Oncol Nurs Forum"},{"key":"2026072315263731600_oyag256-B26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","article-title":"Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG\/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"key":"2026072315263731600_oyag256-B27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026072315263731600_oyag256-B28","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1007\/s00432-021-03582-x","article-title":"Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC","volume":"147","author":"Lee","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026072315263731600_oyag256-B29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.eururo.2011.10.011","article-title":"Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment","volume":"61","author":"Shariat","year":"2012","journal-title":"Eur Urol"},{"key":"2026072315263731600_oyag256-B30","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.eururo.2012.01.049","article-title":"Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity","volume":"61","author":"Tarin","year":"2012","journal-title":"Eur Urol"},{"key":"2026072315263731600_oyag256-B31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.21037\/tau-20-1086","article-title":"Smoking status and pathological response to neoadjuvant chemotherapy among patients with bladder cancer: a pooled analysis","volume":"10","author":"He","year":"2021","journal-title":"Transl Androl Urol"},{"key":"2026072315263731600_oyag256-B32","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.eururo.2007.03.086","article-title":"P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors","volume":"52","author":"Kassouf","year":"2007","journal-title":"Eur Urol"},{"key":"2026072315263731600_oyag256-B33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/SPC.0000000000000505","article-title":"Management of cisplatin-associated toxicities in bladder cancer patients","volume":"14","author":"Desilets","year":"2020","journal-title":"Curr Opin Support Palliat Care"},{"key":"2026072315263731600_oyag256-B34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12894-020-00733-z","article-title":"Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients","volume":"20","author":"Hamid","year":"2020","journal-title":"BMC Urol"},{"key":"2026072315263731600_oyag256-B35","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.4103\/0973-1482.188434","article-title":"Gemcitabine\/cisplatin versus methotrexate\/vinblastine\/doxorubicin\/cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"14","author":"Yu","year":"2018","journal-title":"J Cancer Res Ther"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag256\/68694115\/oyag256.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag256\/68694115\/oyag256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag256\/68694115\/oyag256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:26:43Z","timestamp":1784834803000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag256\/8724520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag256","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"oyag256"}}